Rice Hall James & Associates LLC Boosts Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Rice Hall James & Associates LLC raised its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 41.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,371,080 shares of the biopharmaceutical company’s stock after acquiring an additional 398,942 shares during the period. Rice Hall James & Associates LLC owned approximately 0.46% of Amicus Therapeutics worth $12,916,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in FOLD. Wellington Management Group LLP increased its position in Amicus Therapeutics by 13.5% during the 3rd quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company’s stock worth $255,936,000 after purchasing an additional 2,856,101 shares during the period. Neo Ivy Capital Management acquired a new position in Amicus Therapeutics during the 3rd quarter worth approximately $702,000. Tempus Wealth Planning LLC acquired a new position in Amicus Therapeutics during the 4th quarter worth approximately $259,000. Connor Clark & Lunn Investment Management Ltd. increased its position in Amicus Therapeutics by 51.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 222,934 shares of the biopharmaceutical company’s stock worth $2,381,000 after purchasing an additional 75,807 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in Amicus Therapeutics by 10.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,667,271 shares of the biopharmaceutical company’s stock worth $28,486,000 after purchasing an additional 242,672 shares during the period.

Amicus Therapeutics Price Performance

Shares of NASDAQ:FOLD opened at $9.77 on Tuesday. Amicus Therapeutics, Inc. has a one year low of $8.78 and a one year high of $14.03. The stock has a market cap of $2.92 billion, a PE ratio of -28.74, a price-to-earnings-growth ratio of 1.69 and a beta of 0.61. The business’s fifty day moving average price is $9.60 and its two-hundred day moving average price is $10.43. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.42 and a current ratio of 3.15.

Analyst Ratings Changes

Several equities analysts have issued reports on FOLD shares. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a research report on Monday, January 13th. Morgan Stanley restated an “equal weight” rating and issued a $12.00 price target (down previously from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. Cantor Fitzgerald restated an “overweight” rating and issued a $21.00 price target on shares of Amicus Therapeutics in a report on Wednesday, January 15th. StockNews.com upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, February 12th. Finally, Guggenheim upped their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, Amicus Therapeutics has an average rating of “Moderate Buy” and an average price target of $16.88.

Insiders Place Their Bets

In related news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $10.02, for a total value of $75,150.00. Following the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at approximately $8,884,273.08. This trade represents a 0.84 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 2.20% of the company’s stock.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.